Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ER-100
- Development stage
- Unknown
- Lead developer
- Life Biosciences
- Modality
- Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
ER-100 is an investigational epigenetic therapy candidate designed to address cellular aging through epigenetic reprogramming. It works by delivering genetic instructions for producing three proteins, collectively referred to as OSK, via a modified adeno-associated virus (AAV) vector to retinal cells. These OSK proteins are intended to help reverse epigenetic changes and restore cells to a more youthful state, potentially preserving or restoring vision. The therapy is activated by systemic administration of doxycycline. ER-100 is being developed for age-related optic neuropathies, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
Beyond the preview
Go deeper on ER-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ER-100.